Home・Stock List・Ovid therapeutics Inc

Ovid therapeutics Inc

Closed

SectorHealthcare

2.94 3.89

Buy Sell

Overview

Share price change

24h

Current

Min

2.79

Max

2.9

Key metrics
By Trading Economics
Income	2M -15M
Sales	733K 733K
EPS	-0.08
Profit margin	-2,047.476
Employees	23
EBITDA	566K -16M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+116.26% upside

Dividends
By Acuity
Next Earnings	11 Nov 2026

Market Stats
By TradingEconomics
Market Cap	50M 539M
Previous open	-0.95
Previous close	2.94

News Sentiment

By Acuity

60%

40%

289 / 340 Healthcare

Ovid therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

14 Aug 2026, 19:53 UTC

Social Media

Ovid Therapeutics Inc shares are higher as the company advances its clinical pipeline, with key data releases planned through 2026, attracting positive market sentiment.

13 Aug 2026, 19:16 UTC

Social Media

News

Ovid Therapeutics reported Q2 EPS of -$0.08, surpassing estimates. Shares are trading higher as the company advances its clinical pipeline and maintains $169.8 million in cash.

12 Aug 2026, 19:46 UTC

Ovid Therapeutics Inc shares are higher, supported by positive sentiment from a recent inflation report, despite earlier declines in the session.

7 Aug 2026, 19:26 UTC

Ovid Therapeutics Inc shares are lower today amid broader market dynamics. The stock briefly peaked earlier in the session before declining.

6 Aug 2026, 22:51 UTC

Ovid Therapeutics Inc. shares are lower in after-market trading, declining since Thursday's close despite remaining above its 20-day moving average.

5 Aug 2026, 21:03 UTC

Ovid Therapeutics Inc shares are higher in after-market hours, continuing a positive trend from four consecutive days of gains. No specific news was identified.

4 Aug 2026, 23:01 UTC

Ovid Therapeutics Inc shares are lower in after-market trading, with no specific news identified to explain the decline since Tuesday's close.

3 Aug 2026, 19:11 UTC

News

Ovid Therapeutics shares are higher as Oppenheimer raises the price target to $9.00 from $7.00, maintaining an Outperform rating.

31 Jul 2026, 20:02 UTC

Ovid Therapeutics Inc shares are lower today amid rising Treasury yields and crude oil prices, contributing to broader inflation concerns affecting the biotechnology sector.

27 Jul 2026, 20:07 UTC

Ovid Therapeutics Inc shares are higher during Monday's session, following a cumulative gain since Friday. The stock pulled back from earlier session highs.

22 Jul 2026, 18:46 UTC

Ovid Therapeutics Inc shares are lower amid broader market volatility linked to rising crude oil prices and geopolitical tensions, with no specific news identified.

20 Jul 2026, 19:36 UTC

Ovid Therapeutics Inc shares are lower today, continuing a trend of declines amid broader market pressure from geopolitical tensions and rising oil prices.

Peer Comparison

Price change

Ovid therapeutics Inc Forecast

Price Target

By TipRanks

116.26% upside

12 Months Forecast

Average 6.25 USD 116.26%

High 9 USD

Low 4 USD

Based on 6 Wall Street analysts offering 12 month price targets forOvid therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to Ovid therapeutics Inc - Dist in the past 3 months.

Sentiment

By Acuity

289 / 340 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.